Janney Montgomery Scott LLC Buys 15,392 Shares of Novo Nordisk A/S (NYSE:NVO)

Janney Montgomery Scott LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 5.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 305,178 shares of the company's stock after acquiring an additional 15,392 shares during the quarter. Janney Montgomery Scott LLC's holdings in Novo Nordisk A/S were worth $31,571,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in NVO. CNB Bank acquired a new position in Novo Nordisk A/S in the 4th quarter valued at $26,000. Pacific Center for Financial Services grew its position in shares of Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company's stock valued at $25,000 after purchasing an additional 135 shares during the last quarter. Valued Wealth Advisors LLC bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $28,000. Bell Investment Advisors Inc lifted its position in shares of Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company's stock worth $26,000 after purchasing an additional 127 shares during the last quarter. Finally, Tyler Stone Wealth Management boosted its stake in Novo Nordisk A/S by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company's stock valued at $27,000 after purchasing an additional 146 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on NVO. Cantor Fitzgerald restated an "overweight" rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. UBS Group began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They set a "neutral" rating on the stock. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an "overweight" rating and a $120.00 target price for the company. Finally, BMO Capital Markets started coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They set an "outperform" rating and a $163.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $133.60.

Novo Nordisk A/S Trading Up 1.3 %

Shares of NVO traded up $1.72 during trading hours on Wednesday, hitting $134.64. 3,717,868 shares of the stock traded hands, compared to its average volume of 4,769,915. The business has a fifty day moving average of $127.94 and a 200-day moving average of $114.69. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $604.20 billion, a PE ratio of 46.43, a price-to-earnings-growth ratio of 2.05 and a beta of 0.43. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.